As an Associate Partner in L2 Consulting, Robert Gould has over 15 years of experience in laboratory animal research in both rodents and NHPs. His expertise in behavior and neuropharmacology spans surgical procedures, behavioral testing using classic and novel model development for multiple CNS disorders (schizophrenia, Alzheimer’s Disease, Parkinson’s Disease, Substance Use Disorder, cognitive impairments, sleep disturbances), and translational biomarker assessments of CNS function (PET, fMRI, EEG). This includes catheter implantation, stereotactic implantation of EEG electrodes and cannulae for neurochemical detection as well biochemical/tissue collection. Dr. Gould has also contributed to multiple drug discovery programs including aspects of target validation through preclinical candidate development, examining PK/PD relationships, and biomarker development/implementation.
Dr. Gould is a member or invited presenter at conferences such as The American Society for Pharmacology and Experimental Therapeutics (ASPET), College of Drug Dependence (CPDD) and the American College of Neuropsychopharmacology (ACNP). His current research includes examining how sleep disruptions contribute to CNS disorders including substance use disorder, and how normalization via pharmacological agents targeting GPCRs may contribute to successful treatment strategies.
Specialties: Operant and non-operant behavioral testing (classic models assessing anxiolytic/anti- depressant like effects, drug self-administration; touchscreen cognition assessments); CSF Collection/blood/brain collection; Chronic indwelling catheter implantation; Stereotaxic Surgical Techniques; Telemetry Implantation Techniques (EEG, rodents); CNS biomarker study design, implementation and analysis (EEG, fMRI, PET).
Robert W. Gould Phd